Does Sulfasalazine Still Have Therapeutic Value in the Treatment of Axial Spondyloarthritis? A Real‐World Cohort Study From China
SSZ reduces disease activity, improves quality of life among ax-SpA patients, reduces the incidence of peripheral symptoms, and delays their onset. About one-third of ax-SpA patients develop peripheral symptoms over time, which are associated with poorer functional status and quality of life. Smoking increases this risk, while male gender and SSZ use offer protection.
Authors
- Feng Huang (ORCID: https://orcid.org/0000-0002-2319-873X)
- Jiawen Hu (ORCID: https://orcid.org/0000-0001-8286-0394)
- Jian Zhu (ORCID: https://orcid.org/0000-0002-6244-9917)
- Xiaojian Ji (ORCID: https://orcid.org/0000-0003-4753-191X)
- Shi‐Zhong Yang (ORCID: https://orcid.org/0000-0001-9979-4469)
- Yinan Zhang (ORCID: https://orcid.org/0000-0001-6537-7587)
- Lidong Hu (ORCID: https://orcid.org/0000-0001-5004-187X)
- Yiwen Wang (ORCID: https://orcid.org/0000-0003-2495-6552)
- Jiaxin Zhang (ORCID: https://orcid.org/0000-0002-8105-2333)
- Simin Liao
- Lulu Zeng (ORCID: https://orcid.org/0009-0002-3132-8589)
Institutions
- Chinese PLA General Hospital (CN)
- People's Liberation Army No. 150 Hospital (CN)
- Chinese People’s Liberation Army 263 hospital (CN)
Publication Details
- Journal
- Journal of Evidence-Based Medicine
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1111/jebm.70055
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00